Hormone- and chemotherapy-induced bone loss in breast cancer.
Hormonal and chemotherapies have been shown to have a profound, positive impact on survival in cancer patients but are associated with adverse effects on bone. The abrupt decrease in bone mineral density caused by these therapies is an emerging treatment challenge. In particular, as the aromatase inhibitors are more widely used, studies indicate that there will be an increased fracture risk. Adjuvant therapy with selective estrogen receptor modifiers spares bone loss in postmenopausal women but not in premenopausal women. Thus other strategies to protect bone are needed. This article discusses various treatments that attempt to offset this bone loss--mainly the protective effects of several bisphosphonates.
Coleman
Robert E
RE
Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England, United Kingdom. R.E.Coleman@sheffield.ac.uk
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D017698:Postmenopause; D017697:Premenopause; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators